STIM Earnings

STIM reported its FY2025Q3 earnings on 2025-11-04, showcasing a revenue of 37.30M against an estimate of 37.85M, resulting in a -1.45% surprise. The EPS was -0.13, surpassing the expected -0.11 by -18.18%. The stock experienced a 3.61% price change on the earnings day and a -17.69% change over the next five days, reflecting market reactions to the results.

Following STIM's FY2025Q3 earnings announcement on 2025-11-04, the stock price moved by 3.61% on the day of the release. Over the subsequent five days, it saw a -17.69% change. Historically, STIM's stock price tends to shift by an average of 14.16% in the 10 days leading up to earnings and -4.99% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate STIM's annual revenue to reach 37.22M, while the EPS is projected at -0.13. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between STIM's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, STIM's stock price typically moves by 14.16% in the 10 days before its earnings and -4.99% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of -0.13 and revenue of 37.22M.

The earnings call reflects mixed signals: improved financial performance, but lower gross margins and ongoing CID investigation. Positive aspects include increased treatment and clinic revenues, reduced net loss, and optimistic guidance. However, the Q&A session highlighted risks, such as the CID investigation and vague details on COMP360 profitability and exclusivity. The lack of clear guidance and lower Q1 expectations due to seasonality and weather also contribute to a neutral outlook. The mixed sentiment is balanced by operational improvements and growth in SPRAVATO treatments.